Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by memory loss and multiple cognitive impairments. Current healthcare costs for over 50 million people afflicted with AD are about $818 million and are projected to be $2 billion by 2050. Unfortunately, there are no drugs currently available that can delay and/or prevent the progression of disease in elderly individuals and in AD patients. Loss of synapses and synaptic damage are largely correlated with cognitive decline in AD patients. Women are at a higher lifetime risk of developing AD encompassing two-thirds of the total AD afflicted population. Only about 1-2% of total AD patients can be explained by genetic mutations in APP, PS1, and PS2 genes. Several risk factors have been identified, such as Apolipoprotein E4 genotype, type 2 diabetes, traumatic brain injury, depression, and hormonal imbalance, are reported to be associated with late-onset AD. Strong evidence reveals that antioxidant enriched diets and regular exercise reduces toxic radicals, enhances mitochondrial function and synaptic activity, and improves cognitive function in elderly populations. Current available data on the use of antioxidants in mouse models of AD and antioxidant(s) supplements in diets of elderly individuals were investigated. The use of antioxidants in randomized clinical trials in AD patients was also critically assessed. Based on our survey of current literature and findings, we cautiously conclude that healthy diets, regular exercise, and improved lifestyle can delay dementia progression and reduce the risk of AD in elderly individuals and reverse subjects with mild cognitive impairment to a non-demented state.
ToodayanN (2016) Professor alois Alzheimer (1864-1915): Lest we forget. J Clin Neurosci31, 47–55.
2.
GlennerGG, WongCW (2012) Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. 1984. Biochem Biophys Res Commun425, 534–539.
3.
Montejo de GarciniE, SerranoL, AvilaJ (1986) Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease. Biochem Biophys Res Commun141, 790–796.
4.
AvilaJ (2006) Tau protein, the main component of paired helical filaments. J Alzheimers Dis9, 171–175.
5.
ReddyPH, McWeeneyS (2006) Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant animal models. Neurobiol Aging27, 1060–1077.
6.
SaundersAM, RosesAD, Pericak-VanceMA, DoleKC, StrittmatterWJ, SchmechelDE, SzymanskiMH, McCownN, ManwaringMG, SchmaderK, BreitnerJCS, GoldgaberD, BensonMD, GoldfarbL, BrownWT (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases. Lancet342, 710–711.
BetheaCL, ReddyAP, ChristianFL (2017) How studies of the serotonin system in macaque models of menopause relate to Alzheimer’s disease. J Alzheimers Dis57, 1001–1015.
15.
Chartier-HarlinMC, CrawfordF, HouldenH, WarrenA, HughesD, FidaniL, GoateA, RossorM, RoquesP, HardyJ, MullanM (1991) Early-onset Alzheimer’s disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature353, 844–846.
16.
SchellenbergGD, BirdTD, WijsmanEM, OrrHT, AndersonL, NemensE, WhiteJA, BonnycastleL, WeberJL, AlonsoME,
et al.
(1992) Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science258, 668–671.
17.
Levy-LahadE, LahadA, WijsmanEM, BirdTD, SchellenbergGD (1995) Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer’s disease. Ann Neurol38, 678–680.
18.
StrittmatterWJ, SaundersAM, SchmechelD, Pericak-VanceM, EnghildJ, SalvesenGS, RosesAD (1993) Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A90, 1977–1981.
LambertJC, HeathS, EvenG, CampionD, SleegersK, HiltunenM, CombarrosO, ZelenikaD, BullidoMJ, TavernierB, LetenneurL, BettensK, BerrC, PasquierF, FievetN, Barberger-GateauP, EngelborghsS, De DeynP, MateoI, FranckA, HelisalmiS, PorcelliniE, HanonO, de PancorboMM, LendonC, DufouilC, JaillardC, LeveillardT, AlvarezV, BoscoP, MancusoM, PanzaF, NacmiasB, BossuP, PiccardiP, AnnoniG, SeripaD, GalimbertiD, HannequinD, LicastroF, SoininenH, RitchieK, BlancheH, DartiguesJF, TzourioC, GutI, Van BroeckhovenC, AlperovitchA, LathropM, AmouyelP (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet41, 1094–1099.
22.
ReddyPH, BealMF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med14, 45–53.
23.
GourasGK, TsaiJ, NaslundJ, VincentB, EdgarM, CheclerF, GreenfieldJP, HaroutunianV, BuxbaumJD, XuH, GreengardP, RelkinNR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol156, 15–20.
24.
MurphyMP, BeckettTL, DingQ, PatelE, MarkesberyWR, St ClairDK, LeVineH3rd, KellerJN (2007) Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis27, 301–311.
25.
OddoS, CaccamoA, KitazawaM, TsengBP, LaFerlaFM (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease. Neurobiol Aging24, 1063–1070.
26.
GongCX, IqbalK (2008) Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr Med Chem15, 2321–2328.
27.
Grundke-IqbalI, IqbalK, QuinlanM, TungYC, ZaidiMS, WisniewskiHM (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem261, 6084–6089.
28.
Grundke-IqbalI, IqbalK, TungYC, QuinlanM, WisniewskiHM, BinderLI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A83, 4913–4917.
29.
WeingartenMD, LockwoodAH, HwoSY, KirschnerMW (1975) A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A72, 1858–1862.
30.
KosikKS, OrecchioLD, BakalisS, NeveRL (1989) Developmentally regulated expression of specific tau sequences. Neuron2, 1389–1397.
31.
StanfordPM, ShepherdCE, HallidayGM, BrooksWS, SchofieldPW, BrodatyH, MartinsRN, KwokJB, SchofieldPR (2003) Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain126, 814–826.
32.
UttonMA, GibbGM, BurdettID, AndertonBH, VandecandelaereA (2001) Functional differences of tau isoforms containing 3 or 4 C-terminal repeat regions and the influence of oxidative stress. J Biol Chem276, 34288–34297.
33.
IshiharaT, HongM, ZhangB, NakagawaY, LeeMK, TrojanowskiJQ, LeeVM (1999) Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron24, 751–762.
34.
LewisJ, McGowanE, RockwoodJ, MelroseH, NacharajuP, Van SlegtenhorstM, Gwinn-HardyK, Paul MurphyM, BakerM, YuX, DuffK, HardyJ, CorralA, LinWL, YenSH, DicksonDW, DaviesP, HuttonM (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet25, 402–405.
35.
ProbstA, GotzJ, WiederholdKH, TolnayM, MistlC, JatonAL, HongM, IshiharaT, LeeVM, TrojanowskiJQ, JakesR, CrowtherRA, SpillantiniMG, BurkiK, GoedertM (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol99, 469–481.
36.
ClevelandDW, HwoSY, KirschnerMW (1977) Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol116, 227–247.
37.
LindwallG, ColeRD (1984) Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem259, 5301–5305.
38.
SenguptaA, KabatJ, NovakM, WuQ, Grundke-IqbalI, IqbalK (1998) Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys357, 299–309.
39.
Alonso AdelC, MederlyovaA, NovakM, Grundke-IqbalI, IqbalK (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem279, 34873–34881.
40.
HaaseC, StielerJT, ArendtT, HolzerM (2004) Pseudophosphorylation of tau protein alters its ability for self-aggregation. J Neurochem88, 1509–1520.
41.
HaradaA, OguchiK, OkabeS, KunoJ, TeradaS, OhshimaT, Sato-YoshitakeR, TakeiY, NodaT, HirokawaN (1994) Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature369, 488–491.
42.
IkegamiS, HaradaA, HirokawaN (2000) Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett279, 129–132.
43.
TakeiY, TengJ, HaradaA, HirokawaN (2000) Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol150, 989–1000.
44.
AlonsoAD, Grundke-IqbalI, BarraHS, IqbalK (1997) Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A94, 298–303.
45.
AlonsoAC, Grundke-IqbalI, IqbalK (1996) Alzheimer’s disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med2, 783–787.
46.
AlonsoAC, ZaidiT, Grundke-IqbalI, IqbalK (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A91, 5562–5566.
47.
AlonsoAD, ZaidiT, NovakM, BarraHS, Grundke-IqbalI, IqbalK (2001) Interaction of tau isoforms with Alzheimer’s disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem276, 37967–37973.
48.
AlafuzoffI, IqbalK, FridenH, AdolfssonR, WinbladB (1987) Histopathological criteria for progressive dementia disorders: Clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol74, 209–225.
49.
ArriagadaPV, GrowdonJH, Hedley-WhyteET, HymanBT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42, 631–639.
50.
TomlinsonBE, BlessedG, RothM (1970) Observations on the brains of demented old people. J Neurol Sci11, 205–242.
51.
CashAD, AlievG, SiedlakSL, NunomuraA, FujiokaH, ZhuX, RainaAK, VintersHV, TabatonM, JohnsonAB, Paula-BarbosaM, AvilaJ, JonesPK, CastellaniRJ, SmithMA, PerryG (2003) Microtubule reduction in Alzheimer’s disease and aging is independent of tau filament formation. Am J Pathol162, 1623–1627.
52.
Alonso AdelC, LiB, Grundke-IqbalI, IqbalK (2006) Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A103, 8864–8869.
53.
ArrasateM, MitraS, SchweitzerES, SegalMR, FinkbeinerS (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature431, 805–810.
54.
KayedR, HeadE, ThompsonJL, McIntireTM, MiltonSC, CotmanCW, GlabeCG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science300, 486–489.
55.
SanbeA, OsinskaH, VillaC, GulickJ, KlevitskyR, GlabeCG, KayedR, RobbinsJ (2005) Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A102, 13592–13597.
56.
SotiropoulosI, GalasMC, SilvaJM, SkoulakisE, WegmannS, MainaMB, BlumD, SayasCL, MandelkowEM, MandelkowE, SpillantiniMG, SousaN, AvilaJ, MedinaM, MudherA, BueeL (2017) Atypical, non-standard functions of the microtubule associated Tau protein. Acta Neuropathol Commun5, 91.
57.
MorrisM, MaedaS, VosselK, MuckeL (2011) The many faces of tau. Neuron70, 410–426.
58.
AhmedT, Van der JeugdA, BlumD, GalasMC, D’HoogeR, BueeL, BalschunD (2014) Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. Neurobiol Aging35, 2474–2478.
59.
KimuraT, WhitcombDJ, JoJ, ReganP, PiersT, HeoS, BrownC, HashikawaT, MurayamaM, SeokH, SotiropoulosI, KimE, CollingridgeGL, TakashimaA, ChoK (2014) Microtubule-associated protein tau is essential for long-term depression in the hippocampus. Philos Trans R Soc Lond B Biol Sci369, 20130144.
60.
Mondragon-RodriguezS, Trillaud-DoppiaE, DudilotA, BourgeoisC, LauzonM, LeclercN, BoehmJ (2012) Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J Biol Chem287, 32040–32053.
61.
KobayashiS, TanakaT, SoedaY, AlmeidaOFX, TakashimaA (2017) Local somatodendritic translation and hyperphosphorylation of tau protein triggered by AMPA and NMDA receptor stimulation. EBioMedicine20, 120–126.
ScheffSW, AndersonKJ, DeKoskyST (1985) Strain comparison of synaptic density in hippocampal CA1 of aged rats. Neurobiol Aging6, 29–34.
64.
ScheffSW, ScottSA, DeKoskyST (1991) Quantitation of synaptic density in the septal nuclei of young and aged Fischer 344 rats. Neurobiol Aging12, 3–12.
65.
DeKoskyST, ScheffSW, StyrenSD (1996) Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration5, 417–421.
66.
TerryRD, MasliahE, SalmonDP, ButtersN, DeTeresaR, HillR, HansenLA, KatzmanR (1991) Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol30, 572–580.
67.
ReddyPH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer’s disease. J Neurochem96, 1–13.
68.
DeviL, PrabhuBM, GalatiDF, AvadhaniNG, AnandatheerthavaradaHK (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci26, 9057–9068.
69.
ManczakM, AnekondaTS, HensonE, ParkBS, QuinnJ, ReddyPH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet15, 1437–1449.
70.
ManczakM, ParkBS, JungY, ReddyPH (2004) Differential expression of oxidative phosphorylation genes in patients with Alzheimer’s disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med5, 147–162.
71.
ReddyPH, McWeeneyS, ParkBS, ManczakM, GutalaRV, PartoviD, JungY, YauV, SearlesR, MoriM, QuinnJ (2004) Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet13, 1225–1240.
72.
AbramovAY, CanevariL, DuchenMR (2004) Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci24, 565–575.
GibsonGE, SheuKF, BlassJP (1998) Abnormalities of mitochondrial enzymes in Alzheimer disease. J Neural Transm (Vienna)105, 855–870.
75.
LinMT, BealMF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature443, 787–795.
76.
ReddyPH (2007) Mitochondrial dysfunction in aging and Alzheimer’s disease: Strategies to protect neurons. Antioxid Redox Signal9, 1647–1658.
77.
MillerRJ (1992) Neuronal Ca2+: Getting it up and keeping it up. Trends Neurosci15, 317–319.
78.
Wong-RileyMT (1989) Cytochrome oxidase: An endogenous metabolic marker for neuronal activity. Trends Neurosci12, 94–101.
79.
ReynoldsIJ, MalaiyandiLM, CoashM, RintoulGL (2004) Mitochondrial trafficking in neurons: A key variable in neurodegeneration?J Bioenerg Biomembr36, 283–286.
80.
TangY, ZuckerRS (1997) Mitochondrial involvement in post-tetanic potentiation of synaptic transmission. Neuron18, 483–491.
81.
HagenTM, YoweDL, BartholomewJC, WehrCM, DoKL, ParkJY, AmesBN (1997) Mitochondrial decay in hepatocytes from old rats: Membrane potential declines, heterogeneity and oxidants increase. Proc Natl Acad Sci U S A94, 3064–3069.
82.
RiddleDR, SonntagWE, LichtenwalnerRJ (2003) Microvascular plasticity in aging. Ageing Res Rev2, 149–168.
83.
WallaceDC (1992) Mitochondrial genetics: A paradigm for aging and degenerative diseases?Science256, 628–632.
84.
YanknerBA, LuT, LoerchP (2008) The aging brain. Annu Rev Pathol3, 41–66.
85.
Bach-FaigA, BerryEM, LaironD, ReguantJ, TrichopoulouA, DerniniS, MedinaFX, BattinoM, BelahsenR, MirandaG, Serra-MajemL (2011) Mediterranean diet pyramid today. Science and cultural updates. Public Health Nutr14, 2274–2284.
86.
TrichopoulouA, CostacouT, BamiaC, TrichopoulosD (2003) Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med348, 2599–2608.
87.
MorrisMC, TangneyCC, WangY, BarnesLL, BennettD, AggarwalN (2014) MIND diet score more predictive than DASH or Mediterranean diet scores. Alzheimers Dement10, P166.
JaliliM, PatiS, RathB, BjørklundG, SinghRB (2013) Effect of diet and nutrients on molecular mechanism of gene expression mediated by nuclear receptor and epigenetic modulation. Open Nutraceuticals J6, 27–34.
90.
ScarpaS, FusoA, D’AnselmiF, CavallaroRA (2003) Presenilin 1 gene silencing by S-adenosylmethionine: A treatment for Alzheimer disease?FEBS Lett541, 145–148.
91.
AdlardPA, PerreauVM, PopV, CotmanCW (2005) Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer’s disease. J Neurosci25, 4217–4221.
92.
CotmanCW, BerchtoldNC (2002) Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci25, 295–301.
93.
Lopez-LopezC, LeRoithD, Torres-AlemanI (2004) Insulin-like growth factor I is required for vessel remodeling in the adult brain. Proc Natl Acad Sci U S A101, 9833–9838.
94.
ChengG, HuangC, DengH, WangH (2012) Diabetes as a risk factor for dementia and mild cognitive impairment: A meta-analysis of longitudinal studies. Intern Med J42, 484–491.
95.
LuchsingerJA, ChengD, TangMX, SchupfN, MayeuxR (2012) Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer Dis Assoc Disord26, 101–105.
96.
RobertsRO, KnopmanDS, ChaRH, MielkeMM, PankratzVS, BoeveBF, KantarciK, GedaYE, JackCRJr, PetersenRC, LoweVJ (2014) Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med55, 759–764.
97.
QizilbashN, GregsonJ, JohnsonME, PearceN, DouglasI, WingK, EvansSJW, PocockSJ (2015) BMI and risk of dementia in two million people over two decades: A retrospective cohort study. Lancet Diabetes Endocrinol3, 431–436.
OomuraY, HoriN, ShiraishiT, FukunagaK, TakedaH, TsujiM, MatsumiyaT, IshibashiM, AouS, LiXL, KohnoD, UramuraK, SougawaH, YadaT, WaynerMJ, SasakiK (2006) Leptin facilitates learning and memory performance and enhances hippocampal CA1 long-term potentiation and CaMK II phosphorylation in rats. Peptides27, 2738–2749.
100.
DohertyGH, Beccano-KellyD, YanSD, Gunn-MooreFJ, HarveyJ (2013) Leptin prevents hippocampal synaptic disruption and neuronal cell death induced by amyloid beta. Neurobiol Aging34, 226–237.
101.
El KhouryNB, GratuzeM, PetryF, PaponMA, JulienC, MarcouillerF, MorinF, NichollsSB, CalonF, HebertSS, MaretteA, PlanelE (2016) Hypothermia mediates age-dependent increase of tau phosphorylation in db/db mice. Neurobiol Dis88, 55–65.
102.
GratuzeM, El KhouryNB, TurgeonA, JulienC, MarcouillerF, MorinF, WhittingtonRA, MaretteA, CalonF, PlanelE (2017) Tau hyperphosphorylation in the brain of ob/ob mice is due to hypothermia: Importance of thermoregulation in linking diabetes and Alzheimer’s disease. Neurobiol Dis98, 1–8.
103.
CorradaMM, HaydenKM, Paganini-HillA, BullainSS, DeMossJ, AguirreC, BrookmeyerR, KawasCH (2017) Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ Study. Alzheimers Dement13, 103–110.
104.
KennellySP, LawlorBA, KennyRA (2009) Blood pressure and the risk for dementia: A double edged sword. Ageing Res Rev8, 61–70.
105.
AnsteyKJ, LipnickiDM, LowLF (2008) Cholesterol as a risk factor for dementia and cognitive decline: A systematic review of prospective studies with meta-analysis. Am J Geriatr Psychiatry16, 343–354.
106.
KivipeltoM, SolomonA (2006) Cholesterol as a risk factor for Alzheimer’s disease - epidemiological evidence. Acta Neurol Scand Suppl185, 50–57.
107.
LigthartSA, Moll van CharanteEP, Van GoolWA, RichardE (2010) Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review. Vasc Health Risk Manag6, 775–785.
108.
McGuinnessB, CraigD, BullockR, PassmoreP (2016) Statins for the prevention of dementia. Cochrane Database Syst Rev, CD003160.
109.
RichardsonK, SchoenM, FrenchB, UmscheidCA, MitchellMD, ArnoldSE, HeidenreichPA, RaderDJ, deGomaEM (2013) Statins and cognitive function: A systematic review. Ann Intern Med159, 688–697.
110.
BarnesDE, KaupA, KirbyKA, ByersAL, Diaz-ArrastiaR, YaffeK (2014) Traumatic brain injury and risk of dementia in older veterans. Neurology83, 312–319.
111.
GardnerRC, YaffeK (2014) Traumatic brain injury may increase risk of young onset dementia. Ann Neurol75, 339–341.
112.
LyeTC, ShoresEA (2000) Traumatic brain injury as a risk factor for Alzheimer’s disease: A review. Neuropsychol Rev10, 115–129.
113.
PlassmanBL, HavlikRJ, SteffensDC, HelmsMJ, NewmanTN, DrosdickD, PhillipsC, GauBA, Welsh-BohmerKA, BurkeJR, GuralnikJM, BreitnerJC (2000) Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology55, 1158–1166.
114.
ShivelyS, ScherAI, PerlDP, Diaz-ArrastiaR (2012) Dementia resulting from traumatic brain injury: What is the pathology?Arch Neurol69, 1245–1251.
115.
LehmanEJ, HeinMJ, BaronSL, GersicCM (2012) Neurodegenerative causes of death among retired National Football League players. Neurology79, 1970–1974.
RobertsGW, AllsopD, BrutonC (1990) The occult aftermath of boxing. J Neurol Neurosurg Psychiatry53, 373–378.
118.
WilsonRS, CapuanoAW, BoylePA, HogansonGM, HizelLP, ShahRC, NagS, SchneiderJA, ArnoldSE, BennettDA (2014) Clinical-pathologic study of depressive symptoms and cognitive decline in old age. Neurology83, 702–709.
119.
ReddyAP, ManczakM, YinX, ReddyH (2016) Protective effects of selective serotonin reuptake inhibitor and neurosteroids against Alzheimer’s disease neurons. Alzheimers Dement12, P651.
120.
ScarmeasN, SternY, TangMX, MayeuxR, LuchsingerJA (2006) Mediterranean diet and risk for Alzheimer’s disease. Ann Neurol59, 912–921.
PsaltopoulouT, KyrozisA, StathopoulosP, TrichopoulosD, VassilopoulosD, TrichopoulouA (2008) Diet, physical activity and cognitive impairment among elders: The EPIC-Greece cohort (European Prospective Investigation into Cancer and Nutrition). Public Health Nutr11, 1054–1062.
TangneyCC, KwasnyMJ, LiH, WilsonRS, EvansDA, MorrisMC (2011) Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr93, 601–607.
129.
VercambreMN, GrodsteinF, BerrC, KangJH (2012) Mediterranean diet and cognitive decline in women with cardiovascular disease or risk factors. J Acad Nutr Diet112, 816–823.
130.
CherbuinN, AnsteyKJ (2012) The Mediterranean diet is not related to cognitive change in a large prospective investigation: The PATH Through Life study. Am J Geriatr Psychiatry20, 635–639.
131.
ChanR, ChanD, WooJ (2013) A cross sectional study to examine the association between dietary patterns and cognitive impairment in older Chinese people in Hong Kong. J Nutr Health Aging17, 757–765.
132.
SamieriC, OkerekeOI, EED, GrodsteinF (2013) Long-term adherence to the Mediterranean diet is associated with overall cognitive status, but not cognitive decline, in women. J Nutr143, 493–499.
133.
YeX, ScottT, GaoX, MarasJE, BakunPJ, TuckerKL (2013) Mediterranean diet, healthy eating index 2005, and cognitive function in middle-aged and older Puerto Rican adults.. J Acad Nutr Diet113, 276281.e271–273.
134.
CorleyJ, StarrJM, McNeillG, DearyIJ (2013) Do dietary patterns influence cognitive function in old age?Int Psychogeriatr25, 1393–1407.
135.
KoyamaA, HoustonDK, SimonsickEM, LeeJS, AyonayonHN, ShaharDR, RosanoC, SatterfieldS, YaffeK (2015) Association between the Mediterranean diet and cognitive decline in a biracial population. J Gerontol A Biol Sci Med Sci70, 354–359.
136.
OlssonE, KarlstromB, KilanderL, BybergL, CederholmT, SjogrenP (2015) Dietary patterns and cognitive dysfunction in a 12-year follow-up study of 70 year old men. J Alzheimers Dis43, 109–119.
137.
MatsubaraE, Bryant-ThomasT, Pacheco QuintoJ, HenryTL, PoeggelerB, HerbertD, Cruz-SanchezF, ChyanYJ, SmithMA, PerryG, ShojiM, AbeK, LeoneA, Grundke-IkbalI, WilsonGL, GhisoJ, WilliamsC, RefoloLM, PappollaMA, ChainDG, NeriaE (2003) Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem85, 1101–1108.
138.
StackmanRW, EckensteinF, FreiB, KulhanekD, NowlinJ, QuinnJF (2003) Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer’s disease by chronic Ginkgo biloba treatment. Exp Neurol184, 510–520.
139.
ConteV, UryuK, FujimotoS, YaoY, RokachJ, LonghiL, TrojanowskiJQ, LeeVM, McIntoshTK, PraticoD (2004) Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J Neurochem90, 758–764.
140.
FengZ, ChangY, ChengY, ZhangBL, QuZW, QinC, ZhangJT (2004) Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer’s disease. J Pineal Res37, 129–136.
141.
NakashimaH, IshiharaT, YokotaO, TeradaS, TrojanowskiJQ, LeeVM, KurodaS (2004) Effects of alpha-tocopherol on an animal model of tauopathies. Free Radic Biol Med37, 176–186.
142.
SungS, YaoY, UryuK, YangH, LeeVM, TrojanowskiJQ, PraticoD (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer’s disease. FASEB J18, 323–325.
143.
QuinnJ, KulhanekD, NowlinJ, JonesR, PraticoD, RokachJ, StackmanR (2005) Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: Implications for clinical trials. Brain Res1037, 209–213.
144.
YangX, YangY, LiG, WangJ, YangES (2008) Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol Neurosci34, 165–171.
145.
SiedlakSL, CasadesusG, WebberKM, PappollaMA, AtwoodCS, SmithMA, PerryG (2009) Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer’s disease. Free Radic Res43, 156–164.
146.
ShenkJC, LiuJ, FischbachK, XuK, PuchowiczM, ObrenovichME, GasimovE, AlvarezLM, AmesBN, LamannaJC, AlievG (2009) The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer’s disease. J Neurol Sci283, 199–206.
147.
HarrisonFE, AllardJ, BixlerR, UsohC, LiL, MayJM, McDonaldMP (2009) Antioxidants and cognitive training interact to affect oxidative stress and memory in APP/PSEN1 mice. Nutr Neurosci12, 203–218.
148.
ChoJY, UmHS, KangEB, ChoIH, KimCH, ChoJS, HwangDY (2010) The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer’s disease in NSE/APPsw-transgenic mice. Int J Mol Med25, 337–346.
149.
DragicevicN, CopesN, O’Neal-MoffittG, JinJ, BuzzeoR, MamcarzM, TanJ, CaoC, OlceseJM, ArendashGW, BradshawPC (2011) Melatonin treatment restores mitochondrial function in Alzheimer’s mice: A mitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res51, 75–86.
150.
MurakamiK, MurataN, OzawaY, KinoshitaN, IrieK, ShirasawaT, ShimizuT (2011) Vitamin C restores behavioral deficits and amyloid-beta oligomerization without affecting plaque formation in a mouse model of Alzheimer’s disease. J Alzheimers Dis26, 7–18.
151.
DumontM, KipianiK, YuF, WilleE, KatzM, CalingasanNY, GourasGK, LinMT, BealMF (2011) Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis27, 211–223.
152.
McManusMJ, MurphyMP, FranklinJL (2011) The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer’s disease. J Neurosci31, 15703–15715.
153.
Garcia-MesaY, Gimenez-LlortL, LopezLC, VenegasC, CristofolR, EscamesG, Acuna-CastroviejoD, SanfeliuC (2012) Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse. Neurobiol Aging33, 1124.e1113–1129.
154.
ClausenA, XuX, BiX, BaudryM (2012) Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer’s disease: Protection against and interruption of progression of amyloid and tau pathology and cognitive decline. J Alzheimers Dis30, 183–208.
155.
Bano OtaloraB, PopovicN, GambiniJ, PopovicM, VinaJ, Bonet-CostaV, ReiterRJ, CamelloPJ, RolMA, MadridJA (2012) Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswe/PS1dE9 transgenic model of Alzheimer disease: Effects of melatonin or ramelteon. Chronobiol Int29, 822–834.
156.
YanJJ, JungJS, KimTK, HasanA, HongCW, NamJS, SongDK (2013) Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease. Biol Pharm Bull36, 140–143.
157.
ShiTY, ZhaoDQ, WangHB, FengS, LiuSB, XingJH, QuY, GaoP, SunXL, ZhaoMG (2013) A new chiral pyrrolyl alpha-nitronyl nitroxide radical attenuates beta-amyloid deposition and rescues memory deficits in a mouse model of Alzheimer disease. Neurotherapeutics10, 340–353.
158.
MontinaroM, UbertiD, MaccarinelliG, BoniniSA, Ferrari-ToninelliG, MemoM (2013) Dietary zeolite supplementation reduces oxidative damage and plaque generation in the brain of an Alzheimer’s disease mouse model. Life Sci92, 903–910.
O’Neal-MoffittG, DelicV, BradshawPC, OlceseJ (2015) Prophylactic melatonin significantly reduces Alzheimer’s neuropathology and associated cognitive deficits independent of antioxidant pathways in AbetaPP(swe)/PS1 mice. Mol Neurodegener10, 27.
161.
JungJS, YanJJ, LiHM, SultanMT, YuJ, LeeHS, ShinKJ, SongDK (2016) Protective effects of a dimeric derivative of ferulic acid in animal models of Alzheimer’s disease. Eur J Pharmacol782, 30–34.
162.
LiZY, ChungYH, ShinEJ, DangDK, JeongJH, KoSK, NahSY, BaikTG, JhooJH, OngWY, NabeshimaT, KimHC (2017) YY-1224, a terpene trilactone-strengthened Ginkgo biloba, attenuates neurodegenerative changes induced by beta-amyloid (1-42) or double transgenic overexpression of APP and PS1 via inhibition of cyclooxygenase-2. J Neuroinflammation14, 94.
163.
MoriT, KoyamaN, TanJ, SegawaT, MaedaM, TownT (2017) Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer’s disease. J Biol Chem292, 11310–11325.
164.
DixitS, FesselJP, HarrisonFE (2017) Mitochondrial dysfunction in the APP/PSEN1 mouse model of Alzheimer’s disease and a novel protective role for ascorbate. Free Radic Biol Med112, 515–523.
165.
La FataG, van VlietN, BarnhoornS, BrandtRMC, EtheveS, ChenalE, GrunenwaldC, SeifertN, WeberP, HoeijmakersJHJ, MohajeriMH, VermeijWP (2017) Vitamin E supplementation reduces cellular loss in the brain of a premature aging mouse model. J Prev Alzheimers Dis4, 226–235.
166.
DongS, HuangX, ZhenJ, Van Halm-LutterodtN, WangJ, ZhouC, YuanL (2018) Dietary vitamin E status dictates oxidative stress outcomes by modulating effects of fish oil supplementation in Alzheimer disease model APPswe/PS1dE9 mice. Mol Neurobiol55, 9204–9219.
167.
ZhangYH, WangDW, XuSF, ZhangS, FanYG, YangYY, GuoSQ, WangS, GuoT, WangZY, GuoC (2018) alpha-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. Redox Biol14, 535–548.
168.
MendelsohnAB, BelleSH, StoehrGP, GanguliM (1998) Use of antioxidant supplements and its association with cognitive function in a rural elderly cohort: The MoVIES Project. Monongahela Valley Independent Elders Survey. Am J Epidemiol148, 38–44.
169.
PerkinsAJ, HendrieHC, CallahanCM, GaoS, UnverzagtFW, XuY, HallKS, HuiSL (1999) Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol150, 37–44.
170.
MasakiKH, LosonczyKG, IzmirlianG, FoleyDJ, RossGW, PetrovitchH, HavlikR, WhiteLR (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology54, 1265–1272.
171.
EngelhartMJ, GeerlingsMI, RuitenbergA, van SwietenJC, HofmanA, WittemanJC, BretelerMM (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA287, 3223–3229.
172.
LuchsingerJA, TangMX, SheaS, MayeuxR (2003) Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol60, 203–208.
173.
GrodsteinF, ChenJ, WillettWC (2003) High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am J Clin Nutr77, 975–984.
174.
ZandiPP, AnthonyJC, KhachaturianAS, StoneSV, GustafsonD, TschanzJT, NortonMC, Welsh-BohmerKA, BreitnerJC (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Arch Neurol61, 82–88.
175.
LaurinD, MasakiKH, FoleyDJ, WhiteLR, LaunerLJ (2004) Midlife dietary intake of antioxidants and risk of late-life incident dementia: The Honolulu-Asia Aging Study. Am J Epidemiol159, 959–967.
176.
FillenbaumGG, KuchibhatlaMN, HanlonJT, ArtzMB, PieperCF, SchmaderKE, DyskenMW, GraySL (2005) Dementia and Alzheimer’s disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann Pharmacother39, 2009–2014.
177.
MorrisMC, EvansDA, TangneyCC, BieniasJL, WilsonRS, AggarwalNT, ScherrPA (2005) Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am J Clin Nutr81, 508–514.
178.
MaxwellCJ, HicksMS, HoganDB, BasranJ, EblyEM (2005) Supplemental use of antioxidant vitamins and subsequent risk of cognitive decline and dementia. Dement Geriatr Cogn Disord20, 45–51.
179.
GraySL, AndersonML, CranePK, BreitnerJC, McCormickW, BowenJD, TeriL, LarsonE (2008) Antioxidant vitamin supplement use and risk of dementia or Alzheimer’s disease in older adults. J Am Geriatr Soc56, 291–295.
180.
DevoreEE, GrodsteinF, van RooijFJ, HofmanA, StampferMJ, WittemanJC, BretelerMM (2010) Dietary antioxidants and long-term risk of dementia. Arch Neurol67, 819–825.
181.
MangialascheF, KivipeltoM, MecocciP, RizzutoD, PalmerK, WinbladB, FratiglioniL (2010) High plasma levels of vitamin E forms and reduced Alzheimer’s disease risk in advanced age. J Alzheimers Dis20, 1029–1037.
182.
MangialascheF, SolomonA, KareholtI, HooshmandB, CecchettiR, FratiglioniL, SoininenH, LaatikainenT, MecocciP, KivipeltoM (2013) Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Exp Gerontol48, 1428–1435.
183.
BasambomboLL, CarmichaelPH, CoteS, LaurinD (2017) Use of vitamin E and C supplements for the prevention of cognitive decline. Ann Pharmacother51, 118–124.
184.
SanoM, ErnestoC, ThomasRG, KlauberMR, SchaferK, GrundmanM, WoodburyP, GrowdonJ, CotmanCW, PfeifferE, SchneiderLS, ThalLJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med336, 1216–1222.
185.
YaffeK, ClemonsTE, McBeeWL, LindbladAS (2004) Impact of antioxidants, zinc, and copper on cognition in the elderly: A randomized, controlled trial. Neurology63, 1705–1707.
186.
PetersenRC, ThomasRG, GrundmanM, BennettD, DoodyR, FerrisS, GalaskoD, JinS, KayeJ, LeveyA, PfeifferE, SanoM, van DyckCH, ThalLJ (2005) Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med352, 2379–2388.
187.
KangJH, CookN, MansonJ, BuringJE, GrodsteinF (2006) A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med166, 2462–2468.
188.
GalaskoDR, PeskindE, ClarkCM, QuinnJF, RingmanJM, JichaGA, CotmanC, CottrellB, MontineTJ, ThomasRG, AisenP (2012) Antioxidants for Alzheimer disease: A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol69, 836–841.
189.
ArltS, Muller-ThomsenT, BeisiegelU, KontushA (2012) Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease. Neurochem Res37, 2706–2714.
190.
DyskenMW, SanoM, AsthanaS, VertreesJE, PallakiM, LlorenteM, LoveS, SchellenbergGD, McCartenJR, MalphursJ, PrietoS, ChenP, LoreckDJ, TrappG, BakshiRS, MintzerJE, HeidebrinkJL, Vidal-CardonaA, ArroyoLM, CruzAR, ZachariahS, KowallNW, ChopraMP, CraftS, ThielkeS, TurveyCL, WoodmanC, MonnellKA, GordonK, TomaskaJ, SegalY, PeduzziPN, GuarinoPD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA311, 33–44.
191.
WolfSA, KronenbergG, LehmannK, BlankenshipA, OverallR, StaufenbielM, KempermannG (2006) Cognitive and physical activity differently modulate disease progression in the amyloid precursor protein (APP)-23 model of Alzheimer’s disease. Biol Psychiatry60, 1314–1323.
192.
ParachikovaA, NicholKE, CotmanCW (2008) Short-term exercise in aged Tg2576 mice alters neuroinflammation and improves cognition. Neurobiol Dis30, 121–129.
193.
YuedeCM, ZimmermanSD, DongH, KlingMJ, BeroAW, HoltzmanDM, TimsonBF, CsernanskyJG (2009) Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer’s disease. Neurobiol Dis35, 426–432.
194.
BelarbiK, SchindowskiK, BurnoufS, CaillierezR, GrosjeanME, DemeyerD, HamdaneM, SergeantN, BlumD, BueeL (2009) Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: Relevance to Alzheimer’s disease. Curr Alzheimer Res6, 152–157.
UmHS, KangEB, KooJH, KimHT, JinL, KimEJ, YangCH, AnGY, ChoIH, ChoJY (2011) Treadmill exercise represses neuronal cell death in an aged transgenic mouse model of Alzheimer’s disease. Neurosci Res69, 161–173.
197.
LiuHL, ZhaoG, ZhangH, ShiLD (2013) Long-term treadmill exercise inhibits the progression of Alzheimer’s disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice. Behav Brain Res256, 261–272.
198.
BoH, KangW, JiangN, WangX, ZhangY, JiLL (2014) Exercise-induced neuroprotection of hippocampus in APP/PS1 transgenic mice via upregulation of mitochondrial 8-oxoguanine DNA glycosylase. Oxid Med Cell Longev2014, 834502.
199.
Ohia-NwokoO, MontazariS, LauYS, EriksenJL (2014) Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Mol Neurodegener9, 54.
200.
RevillaS, SunolC, Garcia-MesaY, Gimenez-LlortL, SanfeliuC, CristofolR (2014) Physical exercise improves synaptic dysfunction and recovers the loss of survival factors in 3xTg-AD mouse brain. Neuropharmacology81, 55–63.
201.
XiongJY, LiSC, SunYX, ZhangXS, DongZZ, ZhongP, SunXR (2015) Long-term treadmill exercise improves spatial memory of male APPswe/PS1dE9 mice by regulation of BDNF expression and microglia activation. Biol Sport32, 295–300.
202.
RaoSK, RossJM, HarrisonFE, BernardoA, ReisererRS, ReisererRS, MobleyJA, McDonaldMP (2015) Differential proteomic and behavioral effects of long-term voluntary exercise in wild-type and APP-overexpressing transgenics. Neurobiol Dis78, 45–55.
203.
ChoJ, ShinMK, KimD, LeeI, KimS, KangH (2015) Treadmill running reverses cognitive declines due to Alzheimer disease. Med Sci Sports Exerc47, 1814–1824.
204.
LinTW, ShihYH, ChenSJ, LienCH, ChangCY, HuangTY, ChenSH, JenCJ, KuoYM (2015) Running exercise delays neurodegeneration in amygdala and hippocampus of Alzheimer’s disease (APP/PS1) transgenic mice. Neurobiol Learn Mem118, 189–197.
205.
HerringA, MunsterY, MetzdorfJ, BolczekB, KrusselS, KrieterD, YavuzI, KarimF, RoggendorfC, StangA, WangY, HermannDM, Teuber-HanselmannS, KeyvaniK (2016) Late running is not too late against Alzheimer’s pathology. Neurobiol Dis94, 44–54.
206.
Maliszewska-CynaE, XhimaK, AubertI (2016) A comparative study evaluating the impact of physical exercise on disease progression in a mouse model of Alzheimer’s disease. J Alzheimers Dis53, 243–257.
207.
HuttenrauchM, BraussA, KurdakovaA, BorgersH, KlinkerF, LiebetanzD, Salinas-RiesterG, WiltfangJ, KlafkiHW, WirthsO (2016) Physical activity delays hippocampal neurodegeneration and rescues memory deficits in an Alzheimer disease mouse model. Transl Psychiatry6, e800.
208.
Tapia-RojasC, AranguizF, Varela-NallarL, InestrosaNC (2016) Voluntary running attenuates memory loss, decreases neuropathological changes and induces neurogenesis in a mouse model of Alzheimer’s disease. Brain Pathol26, 62–74.
209.
GratuzeM, JulienJ, MorinF, MaretteA, PlanelE (2017) Differential effects of voluntary treadmill exercise and caloric restriction on tau pathogenesis in a mouse model of Alzheimer’s disease-like tau pathology fed with Western diet. Prog Neuropsychopharmacol Biol Psychiatry79, 452–461.
210.
NigamSM, XuS, KritikouJS, MarosiK, BrodinL, MattsonMP (2017) Exercise and BDNF reduce Abeta production by enhancing alpha-secretase processing of APP. J Neurochem142, 286–296.
211.
KooJH, KangEB, OhYS, YangDS, ChoJY (2017) Treadmill exercise decreases amyloid-beta burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer’s disease. Exp Neurol288, 142–152.
212.
DoK, LaingBT, LandryT, BunnerW, MersaudN, MatsubaraT, LiP, YuanY, LuQ, HuangH (2018) The effects of exercise on hypothalamic neurodegeneration of Alzheimer’s disease mouse model. PLoS One13, e0190205.
213.
ZhangJ, GuoY, WangY, SongL, ZhangR, DuY (2018) Long-term treadmill exercise attenuates Abeta burdens and astrocyte activation in APP/PS1 mouse model of Alzheimer’s disease. Neurosci Lett666, 70–77.
214.
LautenschlagerNT, CoxKL, FlickerL, FosterJK, van BockxmeerFM, XiaoJ, GreenopKR, AlmeidaOP (2008) Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial. JAMA300, 1027–1037.
215.
LamLC, ChauRC, WongBM, FungAW, LuiVW, TamCC, LeungGT, KwokTC, ChiuHF, NgS, ChanWM (2011) Interim follow-up of a randomized controlled trial comparing Chinese style mind body (Tai Chi) and stretching exercises on cognitive function in subjects at risk of progressive cognitive decline. Int J Geriatr Psychiatry26, 733–740.
216.
NagamatsuLS, HandyTC, HsuCL, VossM, Liu-AmbroseT (2012) Resistance training promotes cognitive and functional brain plasticity in seniors with probable mild cognitive impairment. Arch Intern Med172, 666–668.
217.
VarelaS, AyanC, CancelaJM, MartinV (2012) Effects of two different intensities of aerobic exercise on elderly people with mild cognitive impairment: A randomized pilot study. Clin Rehabil26, 442–450.
218.
SuzukiT, ShimadaH, MakizakoH, DoiT, YoshidaD, ItoK, ShimokataH, WashimiY, EndoH, KatoT (2013) A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. PLoS One8, e61483.
219.
Fiatarone SinghMA, GatesN, SaigalN, WilsonGC, MeiklejohnJ, BrodatyH, WenW, SinghN, BauneBT, SuoC, BakerMK, ForoughiN, WangY, SachdevPS, ValenzuelaM (2014) The Study of Mental and Resistance Training (SMART) study-resistance training and/or cognitive training in mild cognitive impairment: A randomized, double-blind, double-sham controlled trial. J Am Med Dir Assoc15, 873–880.
220.
(2017) Randomized trial on the effects of a combined physical/cognitive training in aged MCI subjects: The Train the Brain study. Sci Rep7, 39471.
221.
ChristofolettiG, OlianiMM, GobbiS, StellaF, Bucken GobbiLT, Renato CanineuP (2008) A controlled clinical trial on the effects of motor intervention on balance and cognition in institutionalized elderly patients with dementia. Clin Rehabil22, 618–626.
222.
EggermontLH, SwaabDF, HolEM, ScherderEJ (2009) Walking the line: A randomised trial on the effects of a short term walking programme on cognition in dementia. J Neurol Neurosurg Psychiatry80, 802–804.
223.
KemounG, ThibaudM, RoumagneN, CaretteP, AlbinetC, ToussaintL, PaccalinM, DugueB (2010) Effects of a physical training programme on cognitive function and walking efficiency in elderly persons with dementia. Dement Geriatr Cogn Disord29, 109–114.
224.
YaguezL, ShawKN, MorrisR, MatthewsD (2011) The effects on cognitive functions of a movement-based intervention in patients with Alzheimer’s type dementia: A pilot study. Int J Geriatr Psychiatry26, 173–181.
225.
VreugdenhilA, CannellJ, DaviesA, RazayG (2012) A community-based exercise programme to improve functional ability in people with Alzheimer’s disease: A randomized controlled trial. Scand J Caring Sci26, 12–19.
226.
HolthoffVA, MarschnerK, ScharfM, StedingJ, MeyerS, KochR, DonixM (2015) Effects of physical activity training in patients with Alzheimer’s dementia: Results of a pilot RCT study. PLoS One10, e0121478.
